Well-known for his experience in pediatric psychopharmacology, Sallee has been an important adviser and consultant to Ironshore on the development of the company's investigational drug products, HLD-100 (amphetamine) and HLD-200 (methylphenidate), since 2011.
David Lickrish, Highland's president and CEO, said, "In his capacity as chief medical officer, Sallee will oversee the clinical development of Ironshore's pipeline. His expertise in ADHD, in conjunction with his extensive experience in clinical trials, will be instrumental as we complete the phase III trial of HLD-200. Results from this study are expected prior to year end."
Previously, Sallee was a professor of psychiatry and neuroscience at the University of Cincinnati School of Medicine. He also has held the positions of vice chairman and division chief of child psychiatry at Cincinnati Children's Hospital Medical Center. Sallee founded the Pediatric Pharmacology Research Unit (PPRU) at Cincinnati Children's Hospital and is credited with supporting pediatric labeling for over 50 marketed drugs including Adderall XR, Concerta and Vyvanse.
Sallee's research has been continuously funded by the NIH since 1990.